Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide
Yang Shen,Ya-Kai Fu,Yong-Mei Zhu,Yin-Jun Lou,Zhao-Hui Gu,Jing-Yi Shi,Bing Chen,Chao Chen,Hong-Hu Zhu,Jiong Hu,Wei-Li Zhao,Jian-Qing Mi,Li Chen,Hong-Ming Zhu,Zhi-Xiang Shen,Jie Jin,Zhen-Yi Wang,Jun-Min Li,Zhu Chen,Sai-Juan Chen
DOI: https://doi.org/10.1016/j.ebiom.2015.04.006
IF: 11.205
2015-01-01
EBioMedicine
Abstract:Background: Acute promyelocytic leukemia (APL) is a model for synergistic target cancer therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which yields a very high 5-year overall survival (OS) rate of 85 to 90%. Nevertheless, about 15% of APL patients still get early death or relapse. We performed this study to address the possible impact of additional gene mutations on the outcome of APL.Methods: We included a consecutive series of 266 cases as training group, and then validated the results in a testing group of 269 patients to investigate the potential prognostic gene mutations, including FLT3-ITD or -TKD, N-RAS, C-KIT, NPM1, CEPBA, WT1, ASXL1, DNMT3A, MLL (fusions and PTD), IDH1, IDH2 and TET2.Results: More high-risk patients (50.4%) carried additional mutations, as compared with intermediate-and low-risk ones. The mutations of epigenetic modifier genes were associated with poor prognosis in terms of disease-free survival in both training (HR = 6.761, 95% CI 2.179-20.984; P = 0.001) and validation (HR = 4.026, 95% CI 1.089-14.878; P = 0.037) groups. Sanz risk stratification was associated with CR induction and OS.Conclusion: In an era of ATRA/ATO treatment, both molecular markers and clinical parameter based stratification systems should be used as prognostic factors for APL. (C) 2015 The Authors. Published by Elsevier B.V.